The trials that support it were conducted in a population with a specific metabolic condition, and generalizing those results to general obesity is not straightforward
They assess whether a patient meets the necessary eligibility criteria for weight loss treatment with Ozempic For instance, it might be appropriate for someone with obesity or overweight with at least one weight related condition
As with any medication, patients should consult their healthcare provider before starting Rybelsus to discuss its benefits, potential side effects, and individual suitability for treatment
The cardiovascular protective mechanisms of GLP-1 receptor agonists are thought to include: Improved glycaemic control , reducing endothelial dysfunction associated with hyperglycaemia Weight reduction , decreasing metabolic stress and inflammation Blood pressure lowering , potentially through effects on fluid balance and vascular function Favourable lipid profile changes , including modest reductions in LDL cholesterol and triglycerides Anti-inflammatory effects , reducing systemic markers of inflammation such as C-reactive protein [20] [21] Regulatory bodies including the MHRA and EMA have not identified thrombotic events as a specific safety concern with GLP-1 receptor agonists